The sale came out of ARKG. We break down the rest of the day and ARK's longer-term record.

Generated from ARK's own holdings data.
ARK's ARK Invest sold an estimated $11.5M of Personalis Inc (PSNL) on 13 Oct 2026, through ARKG. No other trade that day was bigger.
Little money moved in or out of the funds that day, so the 15% change in this holding was a decision rather than a side effect.
This isn't a one-off. Across 5 trades in 30 days, ARK has sold a net $40.9M of the stock.
ARK made 15 real moves that day, once money flowing in and out of the funds is stripped out:
| Stock | Funds | Est. value |
|---|---|---|
| PSNL Personalis IncSold 5 days running | ARKG | −$11.5M |
| CDNA Caredx IncSold 6 days running | ARKG | −$4.8M |
| META Meta Platforms Inc | ARKK | −$3.4M |
| CMPS Compass Pathways PLC | ARKG | +$3.3M |
| ALMR Alamar Biosciences IncBought after a 36% drop this week | ARKG | +$2.5M |
| CRSP CRISPR Therapeutics AGBought after a 10% drop this week | ARKG | +$2.3M |
Across the month, the money has gone mostly into Nvidia Corp ($81.0M), CoreWeave Inc ($53.9M), Veracyte Inc ($43.5M). On the other side, it has been cutting Advanced Micro Devices ($136.4M), 10X Genomics Inc ($94.6M), Robinhood Markets Inc ($58.1M).
ARKG is beating the index this year: +70.8% versus +15.0%.
Over the past month ARKG returned +8.6% to the index's +2.1%. The biggest contributors: Twist Bioscience Corp (+20%, 8% of the fund), Illumina Inc (+37%, 4% of the fund), 10X Genomics Inc (+13%, 10% of the fund).
The last 12 months tell a different story — ARKG +63.0% versus the index's +20.4%, a 43-point gap.
The five-year record shows a 123-point gap. At its worst, in Apr 2025, ARKG was 84% below its Jan 2021 high, and it is still 56% short of it.
| To date | 1 month | YTD | 1 year | 5 years |
|---|---|---|---|---|
| ARKG | +8.6% | +70.8% | +63.0% | -31.6% |
| S&P 500 (SPY) | +2.1% | +15.0% | +20.4% | +91.9% |
| Nasdaq-100 (QQQ) | +4.5% | +21.7% | +27.0% | +115.0% |
ETFpeek is an independent research tool and is not affiliated with ARK Invest or Cathie Wood. Figures are estimates from public fund data, shown for information only — not financial advice. Past performance does not indicate future results.